PCI Biotech Holding (NO) - Successful completion of the third dose group in the Amphinex study. Continued good tolerability and strong tumour response is reported, with an apparent high treatment specificity for cancer cells
Continued good tolerability and strong tumour response is reported, with an apparent high treatment specificity for cancer cells
Oslo, 16 March 2010 - PCI Biotech reported today that it has completed the treatment of the third dose group in the phase I/II study of its proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin in cancer patients. Complete clinical regression of all evaluable treated tumours is observed within a few weeks of treatment also on patients at the third dose level, although one patient died of the underlying disease before complete clinical regression could be achieved. No drug-related serious adverse events have been reported.
To date eleven patients have been given a single photochemical internalisation (PCI) treatment with Amphinex®. Patients with osteosarcoma (1) and squamous cell carcinoma (7) of the Head & Neck and adenocarinoma (3) of the breast have been included and the effectiveness of the PCI treatment seems to be similar across all cancers treated so far. The PCI-technology could therefore potentially be used for local treatment of several different cancers. Three serious adverse events have been recorded; however not deemed drug-related by the investigator.
The investigators at University College Hospital (UCH) in London have observed an apparent high specificity for cancer cells of the PCI treatment. Tumours of very different depths have been treated and it seems that mainly the cancer cells are killed by the treatment, leaving the healthy tissue underneath the tumour largely unaffected. In addition, one patient with a tumour under the skin has been effectively treated with superficial illumination without ulceration of the skin.
"The results of treatment in the patients seen so far continue to be very impressive. While this study is primarily aimed at investigating the safety of Amphinex®, the tolerability of normal tissues is an interesting observation that would prove highly beneficial in clinical practice.", says Principal Investigator Colin Hopper at UCH in London.
When activated by light, Amphinex® promotes effective local delivery of a variety of therapeutic molecules, e.g. bleomycin, through triggered endosomal release. The primary objective of the UCH study is to assess the maximum tolerated dose of Amphinex®, in PCI treatment with bleomycin. Secondary objectives include determination of the antitumor activity of the treatment, as well as the pharmacokinetics of Amphinex®. Preliminary analysis of the pharmacokinetic data indicates that Amphinex® has a half-life in blood of about 18 days. Amphinex® also seems to be present in the skin for a prolonged period, but is barely detectable 3 months after administration. The absence of drug related side effects in the study suggests that the slow kinetics does not impose any additional safety concern.
The patients at the fourth dose level of Amphinex® will be treated as soon as possible, and the study is expected to be completed within 2010.
About PCI Biotech PCI Biotech is a Norwegian biopharmaceutical company developing a novel light directed drug delivery system based on its patented photochemical internalisation (PCI) technology. Originating from world leading research at the Norwegian Radium Hospital, the PCI method involves first injecting Amphinex® and thereafter the therapeutic drug to be specifically delivered to the diseased cells. When these are illuminated the cells' endosomes are ruptured to allow successful intracellular delivery of the drug.
PCI can enhance the delivery of all molecules taken into the cell by endocytosis. This includes most types of macromolecules, drugs carried by antibodies or nanoparticles, as well as some small molecule drugs. In addition, PCI enables the use of more toxic compounds by restricting their effects to the target site.
PCI Biotech follows a dual strategy of using its technology to improve the effect both of existing drugs and for emerging treatments such as gene therapy. PCI Biotech's first clinical study couples the proven photosensitiser Amphinex® with the cytotoxic agent bleomycin. Other studies are planned for the delivery of other cancer drugs in relevant indications.
For more information visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker Per Walday, CEO, email@example.com, Mobile: +47 917 93 429 Bernt-Olav Røttingsnes, CFO, firstname.lastname@example.org, Mobile: +47 913 47 021
International media inquiries: Richard Hayhurst, Schwartz Commuications UK Limited RHayhurst@schwartz-pr.co.uk , Mobile: +44 (0)7950 878 218
This information is subject of the disclosure requirements acc. to ?-12 vphl (Norwegian Securities Trading Act)
Create value through communication
Visit us here.<http://www.hugingroup.com/> - Unsubscribe<http://www.huginonline.com/plsql/try/unsubscribe.unsub>
Posted: March 2010